Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | MARS1 | P56192 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843300 | 0.88 | SMN1; SMN2 (0.37) | CRHR1ALDH1A1POLB | |
| SCHEMBL3839759 | 0.86 | CRHR1 (0.39) | CRHR1POLBHSD11B1MARS1 | |
| SCHEMBL3843615 | 0.81 | CRHR1 (0.40) | CRHR1POLBHSD11B1MARS1CNKSR1 | |
| SCHEMBL3844049 | 0.80 | CRHR1 (0.41) | CRHR1ALDH1A1POLBHSD11B1CNKSR1 | |
| SCHEMBL3843569 | 0.79 | CRHR1 (0.44) | CRHR1HSD11B1 | |
| SCHEMBL3843991 | 0.78 | CRHR1 (0.38) | CRHR1ALDH1A1POLBHSD11B1KMT2A | |
| SCHEMBL3843703 | 0.78 | CRHR1 (0.38) | CRHR1DPP4DPP8MARS1CD38 | |
| SCHEMBL3367520 | 0.76 | CRHR1 (0.43) | CRHR1DPP4DPP8HTT | |
| SCHEMBL3841771 | 0.75 | CRHR1 (0.41) | CRHR1DPP4DPP8MARS1CD38 | |
| SCHEMBL3364750 | 0.75 | CRHR1 (0.48) | CRHR1ALDH1A1DPP4DPP8HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007753-B1 | HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238765-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA1, GABRA2, GABRA3 | CRHR1 96/4885ALDH1A1 543/4885POLB 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.